Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Downgrades Flexion Therapeutics to Market Perform

Raymond James analyst Elliot Wilbur downgrades Flexion Therapeutics (NASDAQ:FLXN) from Strong Buy to Market Perform.

October 12, 2021

1 minute read

Raymond James analyst Elliot Wilbur downgrades Flexion Therapeutics (NASDAQ:FLXN) from Strong Buy to Market Perform.

Chinese Government Departments Say Ask Gaming Firms, Platforms To Have To Be Responsible To Protect Minor’s Physical, Mental Health; Says Tells Firms To Implement Measures Against Gaming, Entertainment

Today, 12:13 PM

-Reuters

Today, 12:13 PM

Wells Fargo analyst Colin Langan maintains Autoliv (NYSE:ALV) with a Equal-Weight and raises the price target from $80 to $81.

Today, 12:13 PM

SpaceX has posted a job listing for a “passionate, experienced” mixologist for its “spaceport” near Brownsville, Texas.

Today, 12:13 PM

SVB Leerink analyst Jonathan Chang maintains Immunogen (NASDAQ:IMGN) with a Market Perform and lowers the price target from $6 to $5.